Subjects who have signed an informed consent form prior to any study related activity
Subjects who are able to give voluntary, written informed consent to participate in this study.
Subjects who are able to understand this study and are willing to complete all the study assessments
Female subjects ≥18 years of age with a diagnosis of ER-positive invasive breast cancer. ER-positivity is defined as an Allred score of 3 or more on immunohistochemical analysis.
Female subjects of childbearing age must have a negative pregnancy test (by Beta HCG qualitative analysis), or must have had a history of a surgical sterilisation, or must give history of no menses in the past twelve months
Groups 2 and 3: Subjects scheduled for WLE +/-SLNB or ALND
You may not be if
Subjects who have had surgery in the operated breast in the past 12months
Subjects who have had radiotherapy in the operated breast
Subjects who have had neoadjuvant systemic therapy
Subjects who have had systemic chemotherapy or investigational therapy in the past two years
Subjects who are pregnant or lactating
Subjects who have a known hypersensitivity to 68Ga, bombesin analogues, or GRPR-antagonists
Subjects who have an existing medical condition that would compromise their participation in the study•Subjects with a current or active history of other known cancerin the opinion of the Investigator
